Literature DB >> 21926929

Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? Findings from the Study of Women's Health Across the Nation.

Rebecca C Thurston1, Samar R El Khoudary, Kim Sutton-Tyrrell, Carolyn J Crandall, Ellen Gold, Barbara Sternfeld, Faith Selzer, Karen A Matthews.   

Abstract

OBJECTIVE: Emerging research suggests links between menopausal hot flashes and cardiovascular risk. The mechanisms underlying these associations are unclear due, in part, to the incomplete understanding of the physiology of hot flashes. We aimed to examine the longitudinal associations between hot flashes/night sweats and both inflammatory and hemostatic markers, controlling for cardiovascular risk factors and estradiol concentrations.
METHODS: Participants in the Study of Women's Health Across the Nation (n = 3,199), a longitudinal cohort study, were aged 42 to 52 years at cohort entry. Women completed interviews (hot flashes, night sweats: none, 1-5, and ≥6 d in the past 2 weeks), physical measures (blood pressure, height, weight), and a blood draw (high-sensitivity C-reactive protein, plasminogen activator inhibitor-1, factor VIIc, tissue plasminogen activator antigen [tPA-ag], fibrinogen, glucose, serum estradiol) yearly for 8 years. Hot flashes/night sweats were examined in relation to each inflammatory/hemostatic marker in linear mixed models adjusting for demographic factors, cardiovascular risk factors, and medication use, as well as serum estradiol.
RESULTS: Compared with experiencing no flashes, reporting hot flashes was associated with higher tPA-aglog (hot flashes 1-5 d: percent change, or % change [95% CI], 3.88 [2.22-5.58]; P < 0.0001; ≥6 d: % change [95% CI], 4.11 [1.95-6.32]; P < 0.001) and higher factor VIIclog (hot flashes ≥6 d: % change [95% CI], 2.13 [0.80-3.47]; P < 0.01) in multivariable models. Findings persisted after adjusting for estradiol. Findings for night sweats were similar but attenuated with adjustment.
CONCLUSIONS: Frequent hot flashes were associated with higher factor VIIc and tPA-ag. Hemostatic pathways may be relevant to understanding hot flash physiology and links between hot flashes and cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926929      PMCID: PMC3183159          DOI: 10.1097/gme.0b013e31821f5d39

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  35 in total

Review 1.  Hemostatic risk factors for atherothrombotic disease: an epidemiologic view.

Authors:  A R Folsom
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

Review 2.  Physiology of hot flashes.

Authors:  R R Freedman
Journal:  Am J Hum Biol       Date:  2001 Jul-Aug       Impact factor: 1.937

Review 3.  The clinical implications of endothelial dysfunction.

Authors:  Michael E Widlansky; Noyan Gokce; John F Keaney; Joseph A Vita
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

4.  Ultrasensitive semiautomated chemiluminescent immunoassay for estradiol.

Authors:  Barry G England; George H Parsons; Russell M Possley; Daniel S McConnell; A Rees Midgley
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

5.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 6.  Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation.

Authors:  Mary Cushman
Journal:  Am J Cardiol       Date:  2002-07-03       Impact factor: 2.778

7.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

8.  Evaluation of the kaiser physical activity survey in women.

Authors:  B E Ainsworth; B Sternfeld; M T Richardson; K Jackson
Journal:  Med Sci Sports Exerc       Date:  2000-07       Impact factor: 5.411

Review 9.  Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective.

Authors:  Russell P Tracy
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

10.  Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition.

Authors:  Howard M Kravitz; Patricia A Ganz; Joyce Bromberger; Lynda H Powell; Kim Sutton-Tyrrell; Peter M Meyer
Journal:  Menopause       Date:  2003 Jan-Feb       Impact factor: 2.953

View more
  29 in total

1.  The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.

Authors:  Laura B Harrington; Marc Blondon; Mary Cushman; Andrew M Kaunitz; Jacques E Rossouw; Matthew A Allison; Lisa W Martin; Karen C Johnson; Jan Rosing; Nancy F Woods; Andrea Z LaCroix; Susan R Heckbert; Barbara McKnight; Nicholas L Smith
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

2.  Predictors of vasomotor symptoms among breast cancer survivors.

Authors:  Katherine W Reeves; Michael Pennell; Randi E Foraker; Carolyn J Crandall; Marcia Stefanick; Electra D Paskett
Journal:  J Cancer Surviv       Date:  2018-02-09       Impact factor: 4.442

3.  Residential Exposure to PM2.5 and Ozone and Progression of Subclinical Atherosclerosis Among Women Transitioning Through Menopause: The Study of Women's Health Across the Nation.

Authors:  Chunzhe Duan; Evelyn O Talbott; Rachel Broadwin; Maria Brooks; Karen Matthews; Emma Barinas-Mitchell
Journal:  J Womens Health (Larchmt)       Date:  2019-02-07       Impact factor: 2.681

4.  Vasomotor symptom characteristics: are they risk factors for incident diabetes?

Authors:  Kristen E Gray; Jodie G Katon; Erin S LeBlanc; Nancy F Woods; Lori A Bastian; Gayle E Reiber; Julie C Weitlauf; Karin M Nelson; Andrea Z LaCroix
Journal:  Menopause       Date:  2018-05       Impact factor: 2.953

5.  Vasomotor symptoms and lipid profiles in women transitioning through menopause.

Authors:  Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Ellen B Gold; Barbara Sternfeld; Hadine Joffe; Faith Selzer; Karen A Matthews
Journal:  Obstet Gynecol       Date:  2012-04       Impact factor: 7.661

Review 6.  Vasomotor symptoms: natural history, physiology, and links with cardiovascular health.

Authors:  R C Thurston
Journal:  Climacteric       Date:  2018-02-02       Impact factor: 3.005

7.  Trajectories of Vasomotor Symptoms and Carotid Intima Media Thickness in the Study of Women's Health Across the Nation.

Authors:  Rebecca C Thurston; Samar R El Khoudary; Ping Guo Tepper; Elizabeth A Jackson; Hadine Joffe; Hsiang-Yu Chen; Karen A Matthews
Journal:  Stroke       Date:  2015-11-17       Impact factor: 7.914

8.  Cardiovascular, hemodynamic, neuroendocrine, and inflammatory markers in women with and without vasomotor symptoms.

Authors:  Jennifer L Gordon; David R Rubinow; Rebecca C Thurston; Julia Paulson; Peter J Schmidt; Susan S Girdler
Journal:  Menopause       Date:  2016-11       Impact factor: 2.953

9.  Vasomotor symptoms and lipids/lipoprotein subclass metrics in midlife women: Does level of endogenous estradiol matter? The SWAN HDL Ancillary Study.

Authors:  Alexis Nasr; Karen A Matthews; Maria M Brooks; Daniel S McConnell; Trevor J Orchard; Jeffrey Billheimer; Daniel J Rader; Samar R El Khoudary
Journal:  J Clin Lipidol       Date:  2020-07-08       Impact factor: 4.766

10.  The Association of Inflammation with Premenstrual Symptoms.

Authors:  Ellen B Gold; Craig Wells; Marianne O'Neill Rasor
Journal:  J Womens Health (Larchmt)       Date:  2016-05-02       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.